argenx stock heads for two November healthcare conferences
Published on 11/04/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- argenx management will join the Guggenheim Healthcare Innovation Conference on November 10.
- A second fireside chat is scheduled for the Jefferies London Global Healthcare Conference on November 17.
- Live webcasts and replays will be available through the company investor website.
argenx announced on November 3 that members of its management team will take part in two healthcare investor conferences this month. The schedule was carried by Fidelity, which reproduced the company release.
Two scheduled management appearances
The first event is the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston. argenx management is scheduled for a fireside chat on Tuesday, November 10, at 2:00 p.m. Eastern Time.
The second appearance is planned for the Jefferies London Global Healthcare Conference on Tuesday, November 17, at 8:30 a.m. Greenwich Mean Time. The release did not attach new financial guidance or clinical results to either event, making the dates and webcast access the immediate investor information.
Webcasts set the next checkpoints
Live presentations will be available through the investor section of the argenx website, while replays are expected to remain accessible for approximately 30 days after each presentation. The events give investors two scheduled opportunities to hear management discuss the immunology business and its development portfolio.
argenx stock traded at 804.50 euros on Lang & Schwarz at 10:42 CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of argenx stock.
argenx stock at a glance
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Quote: 804.50 euros on Lang & Schwarz at 10:42 CET on November 4, 2026
European healthcare investors can monitor the wider regional backdrop through current AEX market coverage.
Further updates and scheduled company events are available in more news and analyses on argenx stock.
